300 related articles for article (PubMed ID: 10492912)
1. Functional activated protein C resistance assays: correlation with factor V DNA analysis is better with RVVT-than APTT-based assays.
Favaloro EJ; Mirochnik O; McDonald D
Br J Biomed Sci; 1999; 56(1):23-33. PubMed ID: 10492912
[TBL] [Abstract][Full Text] [Related]
2. Multilaboratory testing of thrombophilia: current and past practice in Australasia as assessed through the Royal College of Pathologists of Australasia Quality Assurance Program for Hematology.
Favaloro EJ; Bonar R; Sioufi J; Wheeler M; Low J; Aboud M; Duncan E; Smith J; Exner T; Lloyd J; Marsden K;
Semin Thromb Hemost; 2005 Feb; 31(1):49-58. PubMed ID: 15706475
[TBL] [Abstract][Full Text] [Related]
3. Laboratory diagnosis of hereditary thrombophilia.
Michiels JJ; Hamulyák K
Semin Thromb Hemost; 1998; 24(4):309-20. PubMed ID: 9763348
[TBL] [Abstract][Full Text] [Related]
4. Use of modified functional assays for activated protein C resistance in patients with basally prolonged aPTT.
Montaruli B; Schinco P; Pannocchia A; Giorgianni A; Borchiellini A; Tamponi G; Pileri A
Thromb Haemost; 1997 Sep; 78(3):1042-8. PubMed ID: 9308751
[TBL] [Abstract][Full Text] [Related]
5. Clinical evaluation of a functional prothrombin time-based assay for identification of factor V Leiden carriers in a group of Italian patients with venous thrombosis.
Gessoni G; Valverde S
Blood Coagul Fibrinolysis; 2007 Oct; 18(7):603-10. PubMed ID: 17890946
[TBL] [Abstract][Full Text] [Related]
6. A 9-year retrospective assessment of laboratory testing for activated protein C resistance: evolution of a novel approach to thrombophilia investigations.
Favaloro EJ; Orsag I; Bukuya M; McDonald D
Pathology; 2002 Aug; 34(4):348-55. PubMed ID: 12190294
[TBL] [Abstract][Full Text] [Related]
7. Comparison of an activated partial thromboplastin time with a Russell viper venom time test in screening for factor V(Leiden) (FVR506Q).
Sweeney JD; Blair AJ; King TC
Am J Clin Pathol; 1997 Jul; 108(1):74-7. PubMed ID: 9208981
[TBL] [Abstract][Full Text] [Related]
8. Improved distinction of factor V wild-type and factor V Leiden using a novel prothrombin-based activated protein C resistance assay.
Wilmer M; Stocker C; Bühler B; Conell B; Calatzis A
Am J Clin Pathol; 2004 Dec; 122(6):836-42. PubMed ID: 15539375
[TBL] [Abstract][Full Text] [Related]
9. [Activated C protein resistance: laboratory study and prevalence of the defect in the Chilean population].
Pereira J; Quiroga T; Goycoolea M; Muñoz B; Hidalgo P; Kaltwasser G; Mezzano D
Rev Med Chil; 1996 Jun; 124(6):663-8. PubMed ID: 9041721
[TBL] [Abstract][Full Text] [Related]
10. Comparison of functional testing for resistance to activated protein C and molecular biological testing for factor V R506Q in 370 patients.
Montes MA; Fox EA; Longtine JA; Dorfman DM
Arch Pathol Lab Med; 1998 Apr; 122(4):325-9. PubMed ID: 9648899
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity, specificity and predictive value of modified assays for activated protein C resistance in children.
Brandt G; Gruppo R; Glueck CJ; Stroop D; Becker A; Pillow A; Wang P
Thromb Haemost; 1998 Mar; 79(3):567-70. PubMed ID: 9531042
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of original and modified APC-resistance tests in unselected outpatients with clinically suspected thrombosis and in healthy controls.
Svensson PJ; Zöller B; Dahlbäck B
Thromb Haemost; 1997 Feb; 77(2):332-5. PubMed ID: 9157592
[TBL] [Abstract][Full Text] [Related]
13. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Russell viper venom-based and activated partial thromboplastin time-based screening assays for resistance to activated protein C.
Herskovits AZ; Lemire SJ; Longtine J; Dorfman DM
Am J Clin Pathol; 2008 Nov; 130(5):796-804. PubMed ID: 18854273
[TBL] [Abstract][Full Text] [Related]
15. A comparison between two activated protein C resistance methods as routine diagnostic tests for factor V Leiden mutation.
Aboud MR; Ma DD
Br J Haematol; 1997 Jun; 97(4):798-803. PubMed ID: 9217178
[TBL] [Abstract][Full Text] [Related]
16. A prothrombinase-based assay for detection of resistance to activated protein C.
Nicolaes GA; Thomassen MC; van Oerle R; Hamulyak K; Hemker HC; Tans G; Rosing J
Thromb Haemost; 1996 Sep; 76(3):404-10. PubMed ID: 8883278
[TBL] [Abstract][Full Text] [Related]
17. Comparative analysis of "APTT vs RVVT" based activated protein C resistance assay in the diagnosis of Factor V Leiden mutation.
Baig MA
Indian J Pathol Microbiol; 2020; 63(2):247-250. PubMed ID: 32317524
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of coagulometric assays in the assessment of protein C anticoagulant activity; variable sensitivity of commercial APTT reagents to the cofactor effect of protein S.
D'Angelo SV; Gilardoni F; D'Angelo A
Thromb Haemost; 1989 Nov; 62(3):861-7. PubMed ID: 2531939
[TBL] [Abstract][Full Text] [Related]
19. Clinical evaluation of a new functional test for detection of activated protein C resistance (Pefakit APC-R Factor V Leiden) at two centers in Europe and the USA.
Schöni R; Quehenberger P; Wu JR; Wilmer M
Thromb Res; 2007; 119(1):17-26. PubMed ID: 16934314
[TBL] [Abstract][Full Text] [Related]
20. Screening for the FV:Q506 mutation--evaluation of thirteen plasma-based methods for their diagnostic efficacy in comparison with DNA analysis.
Tripodi A; Negri B; Bertina RM; Mannucci PM
Thromb Haemost; 1997 Mar; 77(3):436-9. PubMed ID: 9065989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
